Avadel Ev To Free Cash Flow vs Free Cash Flow Yield Analysis

AVDL Stock

USD 10.14 0.17 1.65%

Avadel Pharmaceuticals financial indicator trend analysis is way more than just evaluating Avadel Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Avadel Pharmaceuticals is a good investment. Please check the relationship between Avadel Pharmaceuticals Ev To Free Cash Flow and its Free Cash Flow Yield accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Ev To Free Cash Flow vs Free Cash Flow Yield

Ev To Free Cash Flow vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Avadel Pharmaceuticals Ev To Free Cash Flow account and Free Cash Flow Yield. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Avadel Pharmaceuticals' Ev To Free Cash Flow and Free Cash Flow Yield is -0.05. Overlapping area represents the amount of variation of Ev To Free Cash Flow that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Avadel Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Avadel Pharmaceuticals' Ev To Free Cash Flow and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Free Cash Flow of Avadel Pharmaceuticals PLC are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Ev To Free Cash Flow i.e., Avadel Pharmaceuticals' Ev To Free Cash Flow and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.05

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Avadel Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Avadel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

At this time, Avadel Pharmaceuticals' Selling General Administrative is quite stable compared to the past year. Issuance Of Capital Stock is expected to rise to about 153.4 M this year, although the value of Discontinued Operations will most likely fall to about 4.2 M.

	2021	2022	2023	2024 (projected)
Interest Expense	9.9M	12.3M	9.9M	10.4M
Depreciation And Amortization	815K	1.5M	1.8M	1.7M

Interest Expense Depreciation And Amortization

Avadel Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock Total Equity	Common Stock
Total Assets		0.27	0.55	0.38	0.65	-0.44	0.04	-0.25	0.27	0.55	0.38	0.21	0.89	0.08	0.41	0.72	0.02	0.42	0.37	0.75	-0.4	0.92	-0.17	0.06	-0.26	-0.27
Short Long Term Debt Total	0.27		-0.4	-0.06	-0.13	-0.16	0.9	-0.32	-0.1	0.32	-0.02	-0.01	0.3	-0.3	0.21	0.6	-0.25	0.24	0.23	0.47	-0.12	0.3	0.44	-0.45	-0.2	-0.21
Other Current Liab	0.55	-0.4		0.76	0.26	-0.25	-0.41	0.01	0.34	0.01	0.6	-0.05	0.32	0.52	0.1	0.22	0.36	0.08	0.06	0.49	-0.35	0.34	-0.2	0.59	-0.16	-0.16
Total Current Liabilities	0.38	-0.06	0.76		-0.11	-0.33	-0.14	-0.14	0.55	0.17	0.52	-0.39	0.2	0.43	0.14	0.24	0.38	-0.05	0.1	0.6	-0.44	0.2	0.41	0.5	0.07	0.07
Total Stockholder Equity	0.65	-0.13	0.26	-0.11		-0.29	-0.33	-0.15	0.12	0.44	0.01	0.33	0.67	-0.2	0.38	0.04	0.06	0.32	0.36	-0.01	-0.13	0.7	-0.4	0.05	-0.13	-0.12
Property Plant And Equipment Net	-0.44	-0.16	-0.25	-0.33	-0.29		0.12	0.39	-0.47	-0.62	0.23	0.11	-0.62	0.4	-0.46	-0.24	-0.19	-0.29	-0.46	-0.33	0.82	-0.57	-0.06	0.39	0.32	0.31
Net Debt	0.04	0.9	-0.41	-0.14	-0.33	0.12		-0.14	-0.3	-0.12	0.13	0.16	-0.04	-0.08	-0.02	0.48	-0.19	0.1	0.03	0.34	0.13	-0.01	0.33	-0.28	-0.19	-0.21
Retained Earnings	-0.25	-0.32	0.01	-0.14	-0.15	0.39	-0.14		-0.54	-0.39	0.22	0.21	-0.37	0.03	-0.96	-0.17	-0.55	-0.21	-0.97	-0.2	-0.05	-0.36	-0.12	0.44	0.46	0.42
Accounts Payable	0.27	-0.1	0.34	0.55	0.12	-0.47	-0.3	-0.54		0.43	-0.04	-0.24	0.32	0.12	0.56	0.03	0.49	0.33	0.5	0.25	-0.31	0.3	0.2	-0.02	0.12	0.15
Cash	0.55	0.32	0.01	0.17	0.44	-0.62	-0.12	-0.39	0.43		-0.33	-0.39	0.78	-0.5	0.5	0.34	-0.2	0.33	0.45	0.35	-0.58	0.73	0.3	-0.39	-0.02	-0.02
Non Current Assets Total	0.38	-0.02	0.6	0.52	0.01	0.23	0.13	0.22	-0.04	-0.33		0.21	-0.06	0.62	-0.18	0.35	0.12	0.02	-0.21	0.5	0.07	0.0	-0.07	0.76	0.01	-0.01
Non Currrent Assets Other	0.21	-0.01	-0.05	-0.39	0.33	0.11	0.16	0.21	-0.24	-0.39	0.21		0.07	0.12	-0.14	0.17	0.04	0.28	-0.11	-0.01	0.26	0.14	-0.67	0.01	-0.1	-0.1
Cash And Short Term Investments	0.89	0.3	0.32	0.2	0.67	-0.62	-0.04	-0.37	0.32	0.78	-0.06	0.07		-0.24	0.51	0.62	-0.06	0.43	0.48	0.59	-0.52	0.99	-0.12	-0.29	-0.27	-0.28
Net Receivables	0.08	-0.3	0.52	0.43	-0.2	0.4	-0.08	0.03	0.12	-0.5	0.62	0.12	-0.24		-0.09	0.13	0.48	-0.31	-0.08	0.28	0.4	-0.17	-0.13	0.49	0.07	0.08
Common Stock Shares Outstanding	0.41	0.21	0.1	0.14	0.38	-0.46	-0.02	-0.96	0.56	0.5	-0.18	-0.14	0.51	-0.09		0.18	0.53	0.33	0.99	0.2	-0.04	0.51	0.0	-0.36	-0.44	-0.4
Non Current Liabilities Total	0.72	0.6	0.22	0.24	0.04	-0.24	0.48	-0.17	0.03	0.34	0.35	0.17	0.62	0.13	0.18		-0.22	0.37	0.16	0.92	-0.29	0.64	-0.05	-0.2	-0.31	-0.34
Inventory	0.02	-0.25	0.36	0.38	0.06	-0.19	-0.19	-0.55	0.49	-0.2	0.12	0.04	-0.06	0.48	0.53	-0.22		-0.2	0.56	-0.03	0.17	-0.03	-0.04	0.09	-0.02	0.03
Other Current Assets	0.42	0.24	0.08	-0.05	0.32	-0.29	0.1	-0.21	0.33	0.33	0.02	0.28	0.43	-0.31	0.33	0.37	-0.2		0.26	0.28	-0.33	0.45	-0.21	-0.12	-0.26	-0.26
Other Stockholder Equity	0.37	0.23	0.06	0.1	0.36	-0.46	0.03	-0.97	0.5	0.45	-0.21	-0.11	0.48	-0.08	0.99	0.16	0.56	0.26		0.17	0.0	0.48	-0.01	-0.41	-0.48	-0.44
Total Liab	0.75	0.47	0.49	0.6	-0.01	-0.33	0.34	-0.2	0.25	0.35	0.5	-0.01	0.59	0.28	0.2	0.92	-0.03	0.28	0.17		-0.42	0.61	0.12	0.03	-0.23	-0.25
Property Plant And Equipment Gross	-0.4	-0.12	-0.35	-0.44	-0.13	0.82	0.13	-0.05	-0.31	-0.58	0.07	0.26	-0.52	0.4	-0.04	-0.29	0.17	-0.33	0.0	-0.42		-0.46	-0.21	0.14	0.07	0.09
Total Current Assets	0.92	0.3	0.34	0.2	0.7	-0.57	-0.01	-0.36	0.3	0.73	0.0	0.14	0.99	-0.17	0.51	0.64	-0.03	0.45	0.48	0.61	-0.46		-0.16	-0.25	-0.28	-0.28
Short Term Debt	-0.17	0.44	-0.2	0.41	-0.4	-0.06	0.33	-0.12	0.2	0.3	-0.07	-0.67	-0.12	-0.13	0.0	-0.05	-0.04	-0.21	-0.01	0.12	-0.21	-0.16		0.01	0.36	0.36
Intangible Assets	0.06	-0.45	0.59	0.5	0.05	0.39	-0.28	0.44	-0.02	-0.39	0.76	0.01	-0.29	0.49	-0.36	-0.2	0.09	-0.12	-0.41	0.03	0.14	-0.25	0.01		0.26	0.24
Common Stock Total Equity	-0.26	-0.2	-0.16	0.07	-0.13	0.32	-0.19	0.46	0.12	-0.02	0.01	-0.1	-0.27	0.07	-0.44	-0.31	-0.02	-0.26	-0.48	-0.23	0.07	-0.28	0.36	0.26		1.0
Common Stock	-0.27	-0.21	-0.16	0.07	-0.12	0.31	-0.21	0.42	0.15	-0.02	-0.01	-0.1	-0.28	0.08	-0.4	-0.34	0.03	-0.26	-0.44	-0.25	0.09	-0.28	0.36	0.24	1.0

Click cells to compare fundamentals

Avadel Pharmaceuticals Account Relationship Matchups

Avadel Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	151.4M	311.6M	247.3M	132.8M	164.7M	134.2M
Short Long Term Debt Total	124.7M	130.5M	145.0M	131.0M	35.4M	38.3M
Other Current Liab	3.9M	11.2M	11.5M	8.3M	23.6M	15.7M
Total Current Liabilities	36.0M	15.1M	21M	55.8M	36.9M	29.7M
Total Stockholder Equity	(29.2M)	162.3M	78.2M	(21.1M)	87.7M	47.1M
Property Plant And Equipment Net	4.2M	3.0M	2.9M	2.6M	3.2M	3.0M
Net Debt	114.9M	58.8M	94.3M	57.0M	4.2M	4.0M
Retained Earnings	(391.2M)	(384.2M)	(447.8M)	(585.2M)	(745.5M)	(708.2M)
Accounts Payable	6.1M	2.9M	7.7M	7.9M	11.4M	6.3M
Cash	9.8M	71.7M	50.7M	74.0M	31.2M	28.3M
Non Current Assets Total	69.1M	48.2M	54.8M	31.9M	30.5M	43.1M
Non Currrent Assets Other	39.3M	24.9M	33.8M	(60.0M)	10.5M	7.4M
Cash And Short Term Investments	64.2M	221.4M	157.2M	96.5M	105.1M	72.6M
Net Receivables	10.4M	3.3M	2.4M	2.2M	13.4M	9.7M
Common Stock Shares Outstanding	37.4M	54.9M	58.5M	60.1M	80.2M	84.2M
Liabilities And Stockholders Equity	151.4M	311.6M	247.3M	132.8M	164.7M	134.2M
Non Current Liabilities Total	144.7M	134.3M	148.0M	98.1M	40.1M	57.4M
Inventory	6.2M	4.8M	3.6M	0.0	10.4M	10.9M
Other Current Assets	4.3M	3.3M	35.3M	4.3M	5.3M	4.4M
Other Stockholder Equity	384.4M	566.9M	549.3M	589.8M	855.5M	898.2M
Total Liab	180.6M	149.4M	169.0M	153.9M	77.0M	87.1M
Property Plant And Equipment Gross	10.6M	8.2M	2.9M	2.6M	14.0M	12.4M
Total Current Assets	82.4M	263.5M	192.5M	100.8M	134.2M	91.1M
Accumulated Other Comprehensive Income	(22.8M)	(21.1M)	(23.9M)	(26.3M)	(23.2M)	(22.0M)
Short Term Debt	645K	948K	1.8M	39.6M	1.9M	1.8M
Common Stock Total Equity	427K	429K	583K	586K	527.4K	501.0K
Common Stock	429K	583K	586K	628K	898K	853.1K
Other Liab	20.6M	4.2M	3.9M	5.7M	6.6M	6.3M
Current Deferred Revenue	114K	25.4M	6.5M	7.2M	8.2M	4.2M
Other Assets	39.2M	28.4M	35.0M	12.6M	14.4M	10.2M
Long Term Debt	121.7M	128.2M	142.4M	91.6M	105.4M	110.6M
Property Plant Equipment	544K	359K	285K	2.6M	2.3M	2.2M
Short Term Investments	54.4M	149.7M	106.5M	22.5M	73.9M	64.8M
Net Tangible Assets	(48.5M)	145.4M	61.4M	(38.0M)	(43.7M)	(41.5M)
Retained Earnings Total Equity	(358.0M)	(391.2M)	(384.2M)	(447.8M)	(403.0M)	(423.1M)
Long Term Debt Total	115.7M	121.7M	128.2M	142.4M	163.8M	171.9M
Capital Surpluse	433.8M	434.4M	566.9M	549.3M	631.8M	491.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports:

How To Invest In Avadel

Details

Is Avadel Stock a good investment?

Details

What is Avadel Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.09)

Revenue Per Share

1.036

Quarterly Revenue Growth

26.743

Return On Assets

(0.34)

Return On Equity

(1.00)

The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Avadel Ev To Free Cash Flow vs Free Cash Flow Yield Analysis

Ev To Free Cash Flow vs Free Cash Flow Yield

Ev To Free Cash Flow vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Ev To Free Cash Flow

Free Cash Flow Yield

Avadel Pharmaceuticals fundamental ratios Correlations

Avadel Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Avadel Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Cash And Short Term Investments
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Total Current Assets	+ 0.92	Total Assets
Total Liab	+ 0.92	Non Current Liabilities Total
Net Debt	+ 0.9	Short Long Term Debt Total

Other Stockholder Equity	- 0.97	Retained Earnings
Common Stock Shares Outstanding	- 0.96	Retained Earnings
Short Term Debt	- 0.67	Non Currrent Assets Other
Cash And Short Term Investments	- 0.62	Property Plant And Equipment Net
Cash	- 0.62	Property Plant And Equipment Net
Property Plant And Equipment Gross	- 0.58	Cash